Matrix Metalloproteinase-dependent turnover of cartilage, synovial membrane, and connective tissue is elevated in rats with collagen induced arthritis

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Siebuhr, Anne Sofie ^a   Wang, Jianxia ^b   Karsdal, Morten ^a   Bay Jensen, Anne C ^a   Y, Jin ^b   Q, Zheng ^b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b Nordic Bioscience Beijing   (China)

Author keywords

Cartilage; Collagen balance; Connective tissue; Matrix metalloproteinase; Rheumatoid arthritis; Synovial membrane

Indexed keywords

ACETIC ACID; BETA LACTAMASE CTX II; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; HYDROLASE; MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CARTILAGE; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONNECTIVE TISSUE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; NONHUMAN; PROTEIN DEGRADATION; RAT; SYNOVIUM;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BIOLOGICAL MARKERS; CARTILAGE; COLLAGEN TYPE II; COLLAGEN TYPE III; FEMALE; MATRIX METALLOPROTEINASES; RATS; RATS, INBRED LEW; SYNOVIAL MEMBRANE;

EID: 84866487383     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-195     Document Type: Article

References (46)

1. Buch M, Emery P. The aetiology and pathogenesis of Rheumatoid arthritis. Hospital Parmacist 2002, Ref Type: In Press.
2. Brennan P, Silman A. Why the gender difference in susceptibility to rheumatoid arthritis?. Ann Rheum Dis 1995, 54:694-695. 10.1136/ard.54.9.694, 1009979, 7495337.
3. Macgregor AJ, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000, 43:30-37. 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B, 10643697.
4. Deighton CM, Wentzel J, Cavanagh G, Roberts DF, Walker DJ. Contribution of inherited factors to rheumatoid arthritis. Ann Rheum Dis 1992, 51:182-185. 10.1136/ard.51.2.182, 1005655, 1550401.
5. Rousseau JC, et al. Patients with rheumatoid arthritis have an altered circulatory aggrecan profile. BMC Musculoskelet Disord 2008, 9:74. 10.1186/1471-2474-9-74, 2426686, 18507823.
6. Keyszer G, et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999, 26(2):251-258.
7. Mamehara A, et al. Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs. Kobe J Med Sci 2010, 56:E98-E107.
8. Smith MD. The normal synovium. Open Rheumatol J 2011, 5:100-106. 10.2174/1874312901105010100, 3263506, 22279508.
9. Eyre DR, Muir H. Type III collagen: A major constituent of rheumatoid and normal human synovial membrane. Connect Tissue Res 1975, 4:11-16. 10.3109/03008207509152192, 130225.
10. Lovell CR, Nicholls AC, Jayson MI, Bailey AJ. Changes in the collagen of synovial membrane in rheumatoid arthritis and effect of D-penicillamine. Clin Sci Mol Med 1978, 55:31-40.
11. Weiss JB, et al. Occurrence of type III collagen in inflamed synovial membranes: a comparison between non rheumatoid, rheumatoid, and normal synovial collagens. Biochem Biophys Res Commun 1975, 65:907-912. 10.1016/S0006-291X(75)80471-2, 1098664.
12. Konttinen YT, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999, 58:691-697. 10.1136/ard.58.11.691, 1752794, 10531073.
13. Kim KS, et al. Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int 2011, 31:543-547. 10.1007/s00296-010-1592-1, 20665024.
14. Pap T, et al. Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. Arthritis Rheum 2000, 43:1226-1232. 10.1002/1529-0131(200006)43:6<1226::AID-ANR5>3.0.CO;2-4, 10857781.
15. Lee EG, et al. Ethyl acetate fraction from Cudrania tricuspidata inhibits IL-1beta-induced rheumatoid synovial fibroblast proliferation and MMPs, COX-2 and PGE2 production. Biol Res 2010, 43:225-231.
16. Bonde M, et al. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 1997, 12:1028-1034. 10.1359/jbmr.1997.12.7.1028, 9200001.
17. Rousseau JC, et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2004, 12(6):440-7. 10.1016/j.joca.2004.02.004, 15135140.
18. Smith RK, Heinegard D. Cartilage oligomeric matrix protein (COMP) levels in digital sheath synovial fluid and serum with tendon injury. Equine Vet J 2000, 32:52-58.
19. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990, 36:1328-1332.
20. Leeming D, et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 2011, 16:616-628. 10.3109/1354750X.2011.620628, 21988680.
21. Bay-Jensen AC, et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM-increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 2011, 44:423-429. 10.1016/j.clinbiochem.2011.01.001, 21223960.
22. Barascuk N, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem 2010, 43:899-904. 10.1016/j.clinbiochem.2010.03.012, 20380828.
23. Leeming DJ, et al. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)-assessment of corresponding epitopes. Clin Biochem 2010, 43:1249-1256. 10.1016/j.clinbiochem.2010.07.025, 20709044.
24. Vassiliadis E, et al. Measurement of CO3-610, a Potential Liver Biomarker Derived from Matrix Metalloproteinase-9 Degradation of Collagen Type III, in a Rat Model of Reversible Carbon-Tetrachloride-Induced Fibrosis. Biomark Insights 2011, 6:49-58. 3076019, 21499440.
25. Veidal SS, et al. Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int 2010, 30:1293-1304. 10.1111/j.1478-3231.2010.02309.x, 20666994.
26. Vassiliadis E, et al. Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis. BMC Dermatol 2011, 11:6. 10.1186/1471-5945-11-6, 3072322, 21447148.
27. Lin DY, Chu CM, Sheen IS, Liaw YF. Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases. Dig Dis Sci 1995, 40:21-27. 10.1007/BF02063936, 7821112.
28. Ulrich D, Noah EM, Burchardt ER, Atkins D, Pallua N. Serum concentration of amino-terminal propeptide of type III procollagen (PIIINP) as a prognostic marker for skin fibrosis after scar correction in burned patients. Burns 2002, 28:766-771. 10.1016/S0305-4179(02)00193-6, 12464475.
29. Bay-Jensen AC, et al. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int 2011,
30. Nielsen RH, Christiansen C, Stolina M, Karsdal MA. Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats. Clin Exp Immunol 2008, 152:21-27. 10.1111/j.1365-2249.2008.03594.x, 2384059, 18241229.
31. Bolon B, et al. Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. J Biomed Biotechnol 2011, 2011:569068. 3022224, 21253435.
32. Fereidoni M, Ahmadiani A, Semnanian S, Javan M. An accurate and simple method for measurement of paw edema. J Pharmacol Toxicol Methods 2000, 43:11-14. 10.1016/S1056-8719(00)00089-7, 11091125.
33. Immunodiagnostic Systems Inc. Method 2012, Ref Type: Electronic Citation, Immunodiagnostic Systems Inc..
34. Trojanowska M, LeRoy EC, Eckes B, Krieg T. Pathogenesis of fibrosis: type 1 collagen and the skin. J Mol Med (Berl) 1998, 76:266-274.
35. Jokinen J, et al. Integrin-mediated cell adhesion to type I collagen fibrils. J Biol Chem 2004, 279:31956-31963. 10.1074/jbc.M401409200, 15145957.
36. Dzamba BJ, Wu H, Jaenisch R, Peters DM. Fibronectin binding site in type I collagen regulates fibronectin fibril formation. J Cell Biol 1993, 121:1165-1172. 10.1083/jcb.121.5.1165, 2119696, 8501121.
37. Christensen AF, et al. Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides. J Rheumatol 2010, 37:1113-1120. 10.3899/jrheum.091265, 20436079.
38. Karsdal MA, et al. Biochemical markers of ongoing joint damage in rheumatoid arthritis-current and future applications, limitations and opportunities. Arthritis Res Ther 2011, 13:215. 10.1186/ar3280, 3132026, 21539724.
39. Landewe R, et al. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004, 50:1390-1399. 10.1002/art.20222, 15146408.
40. Bay-Jensen AC, et al. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. Osteoarthritis Cartilage 2008, 16:615-623. 10.1016/j.joca.2007.09.006, 17950629.
41. Charni-Ben TN, et al. The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation. Osteoarthritis Cartilage 2008, 16:1183-1191. 10.1016/j.joca.2008.02.008, 18403221.
42. Jensen LT. The aminoterminal propeptide of type III procollagen. Studies on physiology and pathophysiology. Dan Med Bull 1997, 44:70-78.
43. Myllyla R, Becvar R, Adam M, Kivirikko KI. Markers of collagen metabolism in sera of patients with various rheumatic diseases. Clin Chim Acta 1989, 183:243-252. 10.1016/0009-8981(89)90358-6, 2530010.
44. Hakala M, et al. Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis. Ann Rheum Dis 1995, 54:886-890. 10.1136/ard.54.11.886, 1010038, 7492237.
45. Fueldner C, et al. Identification and evaluation of novel synovial tissue biomarkers in rheumatoid arthritis by laser scanning cytometry. Arthritis Res Ther 2012, 14:R8. 10.1186/ar3682, 3392796, 22251373.
46. Syversen SW, et al. Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Ann Rheum Dis 2010, 69:845-850. 10.1136/ard.2009.122325, 20233753.